Abstract
Background: Cardiac rehabilitation (CR) intervention programs are currently not part of management in patients with atrial fibrillation (AF). We sought to determine the effect of CR compared with a specialized AF clinic (AFC) and usual care on outcomes in patients with AF. Methods: This was a single-centre retrospective cohort study that was carried out using 3 databases: the Hearts in Motion database (2010-2014), prospectively collected data in an AFC (2011-2014), and a retrospective chart review for patients in usual care (2009-2012). Three care pathways were compared: (1) CR; (2) AFC; and (3) usual specialist-based care. The main outcome was AF-related emergency department visits and cardiovascular hospitalizations. Results: Of 566 patients with newly diagnosed AF, 133 (23.5%) patients underwent CR, 197 patients (34.8%) attended the AFC, whereas the remaining 236 (41.7%) were followed in a usual specialist-based care clinic. At 1 year, AF-related emergency department visits and cardiovascular hospitalization rates occurred in 7.5% in the CR group, 16.8% in the AFC group, and 29.2% in usual care. After a propensity matched analysis, usual care was associated with the highest rate of the main outcome (odds ratio, 4.91; 95% confidence interval, 2.09-11.53) compared with CR, as did the AFC compared with CR (odds ratio, 2.75; 95% confidence interval, 1.14-6.6). Conclusions: Among patients with AF, CR was associated with a lower risk of AF-related outcomes. These findings support further study of the use of CR in the management of these patients to determine the optimal model of care for AF patients.
Original language | English |
---|---|
Pages (from-to) | 382-388 |
Number of pages | 7 |
Journal | Canadian Journal of Cardiology |
Volume | 35 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2019 |
Externally published | Yes |
Bibliographical note
Funding Information:Dr Parkash has research grants from Boehringer Ingelheim , Pfizer and Bayer . Dr Giacomontonio has research grants from Pfizer . The other authors have no conflicts of interest to disclose.
Funding Information:
Dr Parkash has research grants from Boehringer Ingelheim, Pfizer and Bayer. Dr Giacomontonio has research grants from Pfizer. The other authors have no conflicts of interest to disclose.
Funding Information:
Supported by Bayer Inc, Boehringer Ingelheim, Pfizer Canada, Capital Health Research Foundation.
Publisher Copyright:
© 2018 Canadian Cardiovascular Society
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine
PubMed: MeSH publication types
- Comparative Study
- Journal Article
- Research Support, Non-U.S. Gov't